FAST FACTS

EAQ221CD: Improving Medication Adherence in Metastatic Breast Cancer using a CONnected CUstomized Treatment Platform (CONCURxP)

ELIGIBILITY CRITERIA

Patient Eligibility Criteria for Step 0 (OPEN Screening Registration)

- 1 Patient must be \geq 18 years of age.
- 2 Patient must be fluent in written and spoken English OR Patient must be fluent in written and spoken Spanish
- 3 Patient must present with new or established pathologically proven HR+ HER2- metastatic breast cancer at the time of Step 0.
- 4 Patient must have initiated any of the CKD4/6 inhibitors (Palbociclib or Ibrance, Ribociclib or Kisqali, Abemaciclib or Verzenio) within 30 days prior to consenting to Step 0 or have received a prescription order with stated intent to initiate within 30 days following Step 0 consent.
 - **NOTE**: Patients who have been treated previously with anticancer treatments other than CDK4/6 inhibitors are eligible.
 - **NOTE**: CDK4/6 inhibitors must be provided/supplied as a single agent blister pack. If the medication is supplied as capsules in a pill bottle (e.g., Ibrance capsules), patient is not eligible.
 - NOTE: Ribociclib (Kisgali) and Abemaciclib (Verzenio) are only available in blister packs. Palbociclib (Ibrance) is the only CDK4/6 inhibitor that might

be available in a capsule formulation. However, this is an outdated formulation and is rarely prescribed as a new start. The format of ordered Palbociclib can be determined based on the prescription order.


- 5 Patients must not have been previously treated with any of the following CDK4/6 inhibitors: Palbociclib or Ibrance, Ribociclib or Kisqali, and Abemaciclib or Verzenio.
- 6 Patients must not already be enrolled in a therapeutic clinical trial that monitors CDK4/6 inhibitors.
- 7 Patient must not be enrolled in a symptom science clinical trial that monitors or intervenes on symptoms related to CDK4/6 inhibitors.
- 8 Patient must confirm that they intend to receive their care or monitoring at an NCORP site.
- 9 Patient must have a personal mobile phone in which they are able and willing to send and receive text messages.
 - **NOTE:** The restriction to those with mobile phone access with text messaging is based on the primary intention of the study which involves the use of text messaging to improve adherence.
- 10 Patient must have an email address.
 - **NOTE:** The restriction to those with an email address is based on the primary intention of the study which involves patients responding to questions regarding their reasons for non-adherence after every missed dose to improve adherence.
- 11 Patient must have the ability to understand and the willingness to sign a written informed consent document.

- NOTE: Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available are not eligible.
- 12 Patient must not have an ECOG Performance Status ≥ 3. OR Patient must not be deemed medically unable to participate in the study by the study investigators or an oncology clinician (i.e., referral to hospice).
- 13 Patient must not be enrolled in other trials offering financial assistance.
 - **NOTE:** Gift cards for survey completion, parking passes, or free medication provided as part of therapeutic trials are not considered financial assistance.

Patient Eligibility Criteria for Step 1 (OPEN Randomization)

- 1 Patient must meet all the eligibility criteria for Step 0 outlined in Section 3.2.1.
- 2 Patient must have signed a written informed consent form.
- 3 Patient must have completed Baseline Survey within 30 days of the date of OPEN Screening Registration (Step 0).
- Patients must have initiated their CDK 4/6 inhibitors within
 30 days of OPEN Screening Registration (Step 0) the date of
 Step 0 Registration.

Patient Schema



"Site staff refers to NCORP site staff/CRA

Non-Patient Participant Intervention Schema

